Cell-surface glycosaminoglycans and anionic phospholipids (GAGs/aPLs)

Cell-surface glycosaminoglycans (GAGs) and anionic phospholipids represent a diverse group of negatively charged molecules on the plasma membrane that serve as critical docking sites for various ligands, including growth factors, cytokines, and pathogens (PubMed: 15134701). GAGs, such as heparan sulfate, are long unbranched polysaccharides that modulate cell signaling and facilitate the entry of numerous viruses, including HIV and SARS-CoV-2, into host cells (PubMed: 22230596). Anionic phospholipids, particularly phosphatidylserine (PS), are typically sequestered in the inner leaflet of the cell membrane but become exposed on the outer surface during apoptosis or within the tumor microenvironment (PubMed: 24632316). This exposure acts as a signaling marker for phagocytes and provides a selective target for therapeutic intervention in oncology and infectious diseases. Drugs targeting these components often utilize charge-based interactions or specific antibody binding to inhibit viral attachment, promote immune-mediated clearance of cancer cells, or deliver molecular payloads directly to diseased tissues (NIH: PMC3513830).

Other names

Cell surface polyanionsAnionic cell surface componentsAcidic phospholipids and glycosaminoglycansNegatively charged cell surface moieties

Drugs targeting these components typically utilize electrostatic interactions or high-affinity protein binding to block viral attachment, neutralize growth factors, or induce antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing exposed anionic lipids (PubMed: 24632316; PubMed: 22230596).